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Seroprevalence of Viral Hepatitis and Sexually
Transmitted Disease Among Adults with
Recently Diagnosed HIV Infection in
Southern Taiwan, 2000–2005: Upsurge in
Hepatitis C Virus Infections Among 
Injection Drug Users
Hsin-Chun Lee,1,2 Nai-Ying Ko,3 Nan-Yao Lee,2 Chia-Ming Chang,2 Wen-Chien Ko1,2*
Background/Purpose: The purpose of this study was to compare the seroprevalence of viral hepatitis and
sexually transmitted disease (STD) co-infections among three populations at risk recently diagnosed with
HIV infection.
Methods: A retrospective review of medical records was performed to determine the prevalence of several
co-infections among adults recently diagnosed with HIV infection between 2000 and 2005 at National
Cheng Kung University Hospital in Tainan, Taiwan.
Results: Among a total of 484 adults, 124 (25.6%) were men having sex with men (MSM), 105 (21.7%)
were heterosexual adults, and 255 (52.7%) were injection drug users (IDUs). The case number of adults
with recently diagnosed HIV infection increased annually, from 27 in 2000 to 142 in 2005 (p < 0.001).
This trend appeared to be attributable to the upsurge in HIV infection among IDUs beginning in 2003. 
At the time of HIV diagnosis, mean CD4+ counts were significantly higher and plasma HIV-1 RNA loads
were lower in the IDU group than the MSM or heterosexual groups. The hepatitis B virus (HBV) carrier rate
was similar in all three groups, with an average rate of 16.5%. The prevalence of treponemal antibody and
Entamoeba histolytica indirect hemagglutination antibody was higher in MSM (37.5% and 9.4%, respec-
tively) than in heterosexuals (19.6% and 7.3%, respectively) or IDUs (3.2% and 2.1%). The seropreva-
lence of hepatitis A virus infection increased with age, with 94.2% (97/103) of patients who were older
than 40 years. Hepatitis C virus (HCV) or HBV-HCV co-infections were noted more often in IDUs (97.9%
and 16.9%, respectively) than in heterosexuals (10.9% and 2.2%, respectively) and MSM (5.3% and 3.6%,
respectively).
Conclusion: There was a recent upsurge in HIV-HCV co-infected IDUs in southern Taiwan. A higher rate
of co-infection with STDs among HIV-infected MSM highlights the need for integrated STD control efforts
in current HIV prevention programs. [J Formos Med Assoc 2008;107(5):404–411]
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The human immunodeficiency virus (HIV) epi-
demic in Taiwan continues to grow. The annual
incidence of reported HIV infections among the
general population was 1.6/100,000 in 1997 and
increased to 3.7/100,000 in 2003.1 Such an explo-
sive HIV epidemic has been related to the spread
of HIV-1 CRF07_BC infections among injection
drug users (IDUs) since 2003.2,3
Due to shared transmission routes, co-infection
with hepatitis B virus (HBV), hepatitis C virus
(HCV), and sexually transmitted diseases (STDs)
are not uncommon among HIV-infected persons.
The prevalence of HIV/HCV co-infection varies
markedly by country, with 35% in the United States
and Europe,4 16.1% in the CAESAR study,5 13.1%
in Australia,6 8.2% in Nigeria,7 and 2.1% in India.8
The prevalence of HIV/HBV co-infection was 9%
in the EuroSIDA cohort,9 6.4% in India,8 and
6.3% in Australia.6 High prevalence of STDs was
reported among HIV-infected patients, with 79.5%
in northern Israel,10 52% in Taiwan,11 25% in New
York,12 and 11.9–13.9% in Baltimore.13 Herpes
simplex virus-2, syphilis, and genital warts were
the three major STDs among people with HIV.10,11
Co-infections with HIV and viral hepatitis or other
STDs are a major public health concern. Early di-
agnosis and implementation of preventive strate-
gies are crucial for reducing further transmission.
In the literature, the prevalence of co-infections
with HIV, viral hepatitis, and STDs varies notably
with regard to the different risk populations. For
example, IDUs had the highest prevalence rate of
HIV/HCV co-infections,5,6,14 and men having sex
with men (MSM) had a higher prevalence of HIV/
HBV co-infections and STDs.11
The life span and quality of life of HIV-infected
individuals have been greatly improved after the
introduction of highly active antiretroviral therapy
(HAART). However, patients co-infected with mul-
tiple hepatitis viruses will experience more com-
plicated clinical problems than those without.
Furthermore, there is an increased risk of progres-
sion to acquired immunodeficiency syndrome
(AIDS) and AIDS-related death among people
with HIV/HCV co-infections.15,16 Chronic HBV
infection among people with HIV infection is the
most important cause of liver cirrhosis and hepa-
tocellular carcinoma, which certainly increases
the likelihood of liver-related mortality.9 HBV in-
fection is an endemic disease in Taiwan, with 
a chronic carrier rate of 15–20% in the general
population prior to mass vaccination.17 The sero-
prevalence of HCV infection in Taiwan is esti-
mated to be 2–5% of the general population and
chronic HCV infection accounts for more than
30% of patients with hepatocellular carcinoma.18
Therefore, there is a substantial number of HIV-
infected patients with multiple infections. How-
ever, there are limited data from Asian countries
regarding the seroprevalence of co-infection among
individuals with HIV infection.
The purpose of this study was to determine
and compare the seroprevalence of viral hepatitis
and STD co-infections among newly diagnosed
HIV patients who acquired the disease via different
modes of transmission. Such information will be
helpful in implementing effective preventive pro-
grams to reduce the spread of not only HIV, but
also HBV, HCV and STDs among specific popula-
tions at risk.
Methods
Study design and population
National Cheng Kung University Hospital was
the site of the study and is one of the referral cen-
ters for HIV/AIDS care in southern Taiwan. There
have been more than 700 cases of HIV infection
since 1992. Serologic tests for co-infections of viral
hepatitis, such as hepatitis A virus (HAV), HBV
and HCV, and syphilis, were routinely performed
for recently diagnosed HIV-infected patients. The
medical records of patients between 2000 and
2005 were retrospectively reviewed. A standard-
ized record form was used to collect data, which
included the results of serologic tests, demographic
data, risk routes of HIV transmission, receipt of an-
tiretroviral therapy, initial plasma HIV RNA loads,
and CD4+ and CD8+ T lymphocyte counts. Patients
who were ≥ 15 years old at the time of HIV diag-
nosis and who had a recognized route of HIV 
Co-infections among adults with recently diagnosed HIV infections
J Formos Med Assoc | 2008 • Vol 107 • No 5 405
infection were included in the analysis. In order
to describe chronological changes in newly diag-
nosed patients who had different transmission
modes, the national HIV epidemiologic data on
Taiwan’s Centers for Disease Control website were
retrieved to compare with the findings of the cur-
rent study.19
Laboratory procedures and definition
The diagnosis of HIV infection was made when
HIV-1 antibody was detected in serum samples
by using a single-microparticle enzyme immu-
noassay (AxSYM HIV 1/2 gO; Abbott GmbH &
Co. KG, Wiesbaden Delkenheim, Germany) and
confirmed by Western blot (New Lav Blot 1;
Biorad, Steenvoorde, France). CD4+ and CD8+
cell counts were determined using flow cyto-
metry (EPICS-XL; Beckman Coulter, CA, USA).
Quantification of HIV plasma viral load (pVL)
was conducted by reverse transcription-polymerase
chain reaction (RT-PCR) (Roche Amplicor, Version
1.5; Roche, Branchburg, NJ, USA) with a lower
detection limit of 400 copies of RNA/mL. Non-
treponemal antibodies to Treponema pallidum were
measured by the rapid plasma regin test (RPR
Card Test; Becton-Dickinson, Maryland, USA) and
treponemal antibodies by T. pallidum hemagglu-
tination (TPHA) assay (SERODIA-TPPA; Fujirebio,
Taoyuan, Taiwan). Patients with TPHA titers
≥ 1:160 were considered to be seroreactive for
T. pallidum infection. Serologic specimens were
tested for IgG antibodies to HAV (HAV-IgG)
(AxSYM HAVAB 2.0; Abbott GmbH Diagnostika,
Wiesbaden-Delkenheim, Germany), hepatitis B
surface antigen (HBsAg), antibodies to HBsAg
(HBsAb) (AxSYM HBsAg [V2] and AUSAB; Abbott
GmbH & Co. KG), and antibodies to HCV (HCV
Ab) (AxSYM HCV version 3.0; Abbott Labora-
tories, Abbot Park, IL, USA). Chronic HBV in-
fection was defined by the presence of serum
HBsAg, and HCV infection was defined by the
presence of HCV Ab in serum. Serum antibodies
to Entamoeba histolytica were determined by indi-
rect hemagglutination (IHA) test (Cellognost-
Amoebiasis; Dade Behring Marburg GmbH,
Marburg, Germany).
Statistical analysis
Statistical analyses were conducted using SPSS
version 11.0 (SPSS Inc., Chicago, IL, USA) for
Windows. Descriptive statistics were calculated
to describe the demographics, baseline immuno-
logic and virologic statuses upon HIV diagnosis,
and use of antiretroviral therapy across three risk
groups. The difference in seroprevalence of viral
hepatitis and STD co-infections was evaluated by
Pearson’s χ2 test. Continuous variables were ana-
lyzed by post hoc Scheffé’s tests. A value of p < 0.05
was considered statistically significant.
Human participant protection
Approval for this study was obtained from the in-
stitutional review board of National Cheng Kung
University Hospital. Informed consent from the
participants was not required due to the retrospec-
tive chart-review design of this study.
Results
Epidemic trends
Overall, 496 patients who were recently diagnosed
with HIV infections visited the study hospital 
between 2000 and 2005. Excluding two children
infected via mother-to-child transmission and 10
with uncertain transmission routes, a total of 484
adults were enrolled in this study. The annual case
numbers of recently diagnosed HIV-infected per-
sons among the three at-risk groups in the study
hospital and Taiwan between 2000 and 2005 are
shown in Figure 1. There was a significant increase
in the number of recently diagnosed cases from
27 in 2000 to 142 in 2005 (p<0.001). Such a trend
could be attributed to the explosive HIV epidemic
among IDUs beginning in 2003, since the case
numbers of HIV-infected MSM and heterosexuals
remained stable during the study period.
Profile of adults with recently diagnosed 
HIV infection
Of the 484 adults, 124 (25.6%) were MSM, 
105 (21.7%) were exposed through heterosexual
sex, and 255 (52.7%) were IDUs. Males (91.7%)
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predominated in the study and the mean age was
35.6 years (range, 18–81 years). At the initial ex-
amination, 123 (26.2%) patients were diagnosed
with AIDS as defined by CD4+ lymphocyte count
< 200 cells/µL. Overall, 46.5% patients had al-
ready taken HAART at the end of 2005. The de-
mographic and baseline clinical characteristics of
study participants across the three at-risk groups
are summarized in Table 1. At the time of HIV 
infection, the mean CD4+ and CD8+ counts were
significantly higher and the plasma HIV-1 RNA
load was significantly lower in IDUs than in MSM
and heterosexuals.
Seroprevalence of hepatitis viruses and 
STD co-infections
Overall, among HIV-infected adults, the prevalence
of TPHA seroreactivity was 15.5% (72/466), and
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Figure 1. Number of adults with recently diagnosed HIV infection at National Cheng Kung University Hospital (NCKUH)
and Taiwan, 2000–2005.
Table 1. Demographic and baseline clinical characteristics of adults recently diagnosed with HIV infections categorized by risk
behaviors, 2000–2005*†
MSM (n = 124) Heterosexual (n = 105) IDU (n = 255) Total (n = 484) p
Male 124 (100) 79 (75.2) 241 (94.5) 444 (91.7) < 0.001
Married 10 (8.1) 56 (53.8) 52 (22.7) 118 (25.8) < 0.001
Age (yr) 30.9 ± 9.5 43.1 ± 14.8 34.7 ± 7.8 35.6 ± 11.0 < 0.001
Years since diagnosis 2.8 ± 1.5 3.7 ± 1.6 1.8 ± 0.7 2.5 ± 1.4 < 0.001
Baseline plasma HIV-1 viral load 4.8 ± 1.0 4.7 ± 0.8 4.2 ± 0.6 4.4 ± 0.8 < 0.001
(log of RNA copies/mL)
Baseline CD8+ counts (cells/µL) 938 ± 528 744 ± 505 1110 ± 498 988 ± 527 < 0.001
Baseline CD4+ counts (cells/µL) 253 ± 217 220 ± 338 462 ± 216 359 ± 272 < 0.001
> 350 37 (31.4) 19 (18.8) 170 (67.7) 226 (48.2)
200–350 28 (23.7) 20 (19.8) 73 (29.1) 121 (25.7)
100–199 11 (9.3) 14 (14.0) 4 (1.6) 29 (6.2)
< 100 42 (35.6) 48 (48.0) 4 (1.6) 94 (20.0)
Receipt of antiretroviral therapy 93 (78.8) 78 (82.1) 33 (14.1) 204 (45.6) < 0.001
*Data presented as n (%) or mean ± standard deviation; †number of people does not always add up to the subgroup case number because of missing data.
MSM = men having sex with men; IDU = injection drug user.
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54.2% (39/72) of those with TPHA seroreactivity
had RPR titers ≥ 1:4. Serum titers of E. histolytica
IHA antibody ≥ 1:128 were noted in 4.7% of 319
patients. Moreover, 65.8% (219/333) had been
infected with HAV, as indicated by the presence of
serum HAV IgG (Table 2). The prevalence of HAV-
IgG increased with age and 94.1% of patients
older than 40 years had detectable HAV-IgG in
their sera (Figure 2). HBV carrier (i.e. presence of
HBsAg in serum) rate was similar across the three
groups, with an average of 16.5% (Table 2). The
prevalence of HCV and HBV/HCV co-infections
among HIV-infected adults was 56.7% and 10.5%,
respectively.
The prevalence of T. pallidum, E. histolytica, HAV,
HCV, and HBV/HCV co-infections were signifi-
cantly different across the three HIV risk groups
(Table 2). Seroreactivity of THPA and E. histolytica
IHA was more often found in MSM (37.5% and
9.4%, respectively) than in heterosexuals (19.6%
and 7.3%, respectively) or IDUs (3.2% and 2.1%,
respectively). HAV-IgG was more frequently found
Figure 2. Age-specific prevalence of hepatitis A virus IgG antibody (HAV-IgG), hepatitis B surface antigen (HBsAg) and
hepatitis C virus antibody (HCV Ab) among recently diagnosed HIV-1-infected adults, 2000–2005.
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Table 2. Seroprevalence among adults recently diagnosed with HIV Infection, 2000–2005
Serologic tests
Case no. with positive result/case no. tested (%)
MSM Heterosexual IDU Total
p
Treponema pallidum
TPHA* 45/120 (37.5) 19/97 (19.6) 8/249 (3.2) 72/466 (15.5) < 0.001
RPR† 29/34 (64.4) 8/19 (24.1) 2/8 (25.0) 39/72 (54.2)
HAV-IgG 30/75 (40.0) 46/54 (85.2) 143/204 (70.1) 219/333 (65.8) < 0.001
HBV
HBsAb 56/93 (60.2) 27/61 (44.3) 133/223 (59.6) 216/377 (57.3) 0.08
HBsAg 20/113 (17.7) 12/94 (12.8) 43/247 (17.4) 75/455 (16.5) 0.544
HCV Ab 6/113 (5.3) 10/92 (10.9) 238/243 (97.9) 254/448 (56.7) < 0.001
HBV/HCV co-infections‡ 4/112 (3.6) 2/92 (2.2) 41/242 (16.9) 47/446 (10.5) < 0.001
Entamoeba histolytica IHA§ 8/85 (9.4) 3/41 (7.3) 4/193 (2.1) 15/319 (4.7) 0.02
*Serum Treponema pallidum hemagglutination (TPHA) titers ≥ 1 : 160; †serum titers ≥ 1 : 4 among patients with TPHA ≥ 1 : 160; ‡presence of both HBsAg
and HCV Ab in serum among patients being tested for both items; §serum E. histolytica indirect hemagglutination (IHA) titers ≥ 1 : 128.
in heterosexuals (85.2%) than in IDUs (70.1%)
or MSM (40.0%). Likewise, chronic HCV or HBV/
HCV co-infections were more often present in IDUs
(97.9% and 16.9%, respectively) than in hetero-
sexuals (10.9% and 2.2%, respectively) or MSM
(5.3% and 3.6%, respectively).
Discussion
After several HIV control policies were launched
by the government, including free access to HAART
since April 1997,1 there was a significant reduc-
tion in morbidity and mortality due to AIDS in
Taiwan.20,21 It was speculated that IDUs in Taiwan
do not usually share needles because of the easy
availability of cheap, disposable needles from drug
stores.22 However, the unexpected upsurge of an
HIV epidemic in Taiwan and the high prevalence
of HCV co-infections (97.9%) among IDUs, as
observed in the present study, suggested that there
was an efficient mode of HIV and HCV transmis-
sion contributing to the current epidemic. Two
recent studies in Taiwan demonstrated that the
majority (>90%) of HIV-1 isolates from IDUs iden-
tified between 2004 and 2005 harbored CRF07_BC
sequences, resembling the dominant strains cir-
culating among IDUs in China,2,3 and travel his-
tory to southwest China and sharing of needles
or apparatuses could be traced in certain affected
individuals.3 Accordingly, this evidence indicated
that parenteral transmission contributes to the
HIV epidemic among IDUs in Taiwan. Dramatic
decrease in the numbers of newly diagnosed HIV-
infected IDUs following the countrywide imple-
mentation of harm reduction programs (including
methadone maintenance therapy and needle/
syringe exchange in convenience stores) begin-
ning in September 2005 was further evidence that
sharing needles or apparatuses is common in this
population and injection behaviors are still the
key targets of intervention.23
Early studies conducted between the 1980s
and 1990s had revealed that parenteral transmis-
sion of blood-borne pathogens among IDUs was
a problem and the prevalence of HCV infections
was as high as 53–82.2%,24–27 which was higher
than in non-injection drug users24,25 and the gen-
eral population.18 Although national policies had
been implemented to interrupt the spread of HCV
infection in Taiwan,28,29 few efforts have been put
into the prevention of HCV transmission in IDUs.
As it shares the same route of transmission with
HIV, the epidemiologic trend of HCV infection
among IDUs would be expected to change fol-
lowing the HIV prevention intervention.
Vertical transmission was the major route of
HBV infections in Taiwan, where more than 90%
of the general population under the age of 40 years
was infected with HBV, and 15–20% of them had
chronic HBV infection before the implementation
of HBV vaccination.17 All the participants in our
study were born before 1984 when national HBV
vaccination programs for neonates began.17 There-
fore, no one had ever received active immuni-
zation before enrolment. A similar trend in HBV
infections across all three at-risk groups, 14.2–
17.4% having HBsAg, was present, as observed
in the general population of Taiwan. Similarly,
Chen et al reported that serum HBsAg could be
noted among 20.3% of IDUs and 18.4% of non-
injectors.30 Those facts support the speculation that
most participants were exposed to HBV during the
perinatal period and, therefore, sexual and/or
parenteral transmission (such as needle sharing
in IDUs) later in adulthood would not further
increase HBV prevalence. Furthermore, from a pub-
lic health viewpoint, mass HBV vaccination will
reduce HBV-related liver morbidity among HIV-
infected individuals born after 1984, as observed
in the general population.17
HAV and E. histolytica are uncommon enteric
pathogens, but humans can contract these path-
ogens via ororectal sex. It can therefore be 
regarded as an STD. With improvements in socio-
economic status and environmental sanitation,
shifting seroepidemiology of HAV infection from
childhood to adulthood has been observed in
many Asian countries.31,32 However, few sero-
conversions occurred in patients younger than
30 years in the study. Overall, one third of our
HIV-infected adults remained susceptible to HAV
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infections. These data indicate the urgent need
for HAV vaccination for the susceptible popula-
tion, in whom HBV or HCV co-infection was not
uncommon, to decrease the risk of hepatitis A out-
break and to avoid severe hepatic injury among
HBV or HCV co-infected individuals.
Recently, invasive amebiasis has been recog-
nized as an emerging parasitic disease in patients
with HIV-1 infections in Taiwan; HIV-infected pa-
tients with a high IHA titer (≥ 128) had a higher
incidence of invasive amebiasis than those with
a lower titer.33 We found that MSM often had sig-
nificant IHA titers, which is consistent with Hung
et al’s report.33 In addition, TPHA seroreactivity
was more frequently present in MSM than in the
other two risk groups at the time of HIV diagnosis.
Such a finding echoed those of two surveillance
studies in Taiwan; one studied gay bathhouses
and another studied male homosexuals at drug/sex
parties. Both studies showed a high prevalence of
syphilis, with 16–25% of infected patients.34,35
These findings highlight the need for more effec-
tive measures to reduce the spread of syphilis in
the MSM population in Taiwan.
Several limitations in this study should be ad-
dressed. First, the full scope of STD co-infections
among HIV-infected individuals was not available
due to the retrospective design. Therefore, we tried
to use serologic markers for syphilis and two patho-
gens (amoeba and HAV), which are also transmis-
sible via intimate contact, to imply the frequency
of STDs by different HIV transmission modes.
Second, information regarding risk behaviors was
retrieved from medical charts, which relied on
self-reported data. It is possible that there was some
under-reporting of either illicit drug use or sex-
ual engagement with men due to legal and iden-
tity considerations. Third, some of our patients
may have exhibited dual or triple HIV risk behav-
iors. However, we assumed that concealed sexual
identity or dual/triple risk behaviors would be
uncommon in our study participants. Fourth, the
sample size of each risk group for E. histolytica
IHA was too small and therefore, the result of
significant difference in seroprevalence of ame-
biasis among the three groups might have a type
II error. Multicenter, large-scale serosurveillance
is needed to further confirm this finding.
In conclusion, many lessons were learned from
the surge in the HIV epidemic in Taiwan. The tar-
gets of public health policies to control HIV trans-
mission should not only include medical care for
HIV-infected persons, but also multidisciplinary
preventive measures for different risk groups. A
higher rate of co-infection with STDs among HIV-
infected MSM highlights the need for integrated
STD control efforts in current HIV prevention
programs.
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